Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Genetically engineered mouse models of esophageal cancer

Genetically engineered mouse models of head and neck cancers

Genetically engineered mouse models in oncology research and cancer medicine

Esophageal adenocarcinoma models: a closer look

Patient-derived tumor models: a suitable tool for preclinical studies on esophageal cancer

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Modeling human gastric cancers in immunocompetent mice

Establishment of Primary Human Esophageal Xenografts: Rationale for Selection and Cancer Model

Mouse models for mesothelioma drug discovery and development

Mouse models of breast cancer in preclinical research

Mouse Models for Head and Neck Squamous Cell Carcinoma

Transgenic and gene knockout mice in gastric cancer research

Study on establishment of esophageal carcinoma animal models

Transgenic Mouse Models in Cancer Research

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Tumorigenicity of Esophageal Cancer Stem Cells (ECSCs) in nude mouse xenograft model

SEMMs: Somatically Engineered Mouse Models. A New Tool for In Vivo Disease Modeling for Basic and Translational Research

Diverse Landscape of Genetically Engineered Mouse Models: Genomic and Molecular Insights into Prostate Cancer

The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer

Experimental mouse models for translational human cancer research

Somatic Genome-Engineered Mouse Models Using In Vivo Microinjection and Electroporation